Abstract P2-03-01: Changes in breast cancer presentation during Covid-19: Experience in an Urban Academic Center

Abstract

Background: The COVID-19 pandemic strained healthcare systems worldwide, delaying breast cancer screening and surgery. In 2019, approximately 80% of breast cancers in the U.S. were diagnosed on screening examinations, with 76.4% of eligible Medicare patients undergoing screening at least every two years. Since the start of the pandemic, many women have been reluctant to seek elective screening mammography, even with the lifting of “lock-down”. We describe the effect of the COVID-19 pandemic on breast cancer presentation at an academic medical center in a city hit hard by the pandemic. Materials and Methods: The institutional IRB-approved Breast Cancer Registry Database was queried for patients enrolled during two time periods, those undergoing first surgical procedure before the start of the pandemic (4/1/2019-3/31/2020) to those the year after the pandemic started (4/1/2020-3/31/2021). Elective cancer surgery was paused for 3 weeks, ending 4/20/2020, and access to routine breast care was limited for 3 months. Variables included age, method of detection, palpability, histologic subtype and staging, neoadjuvant systemic therapy, cancer specific treatments, and radiation uptake. Results: 349 patients were in the 2019 cohort; 246 in the 2020 cohort. No differences in baseline characteristics, including age at presentation, nodal status, or operation type. Fewer cancers were detected on routine mammography post-COVID vs. pre-COVID. Increase in detection of breast cancer through self-exams in 2020 was seen compared to 2019. Palpability on presentation also increased. More patients were treated with neo-adjuvant therapy chemotherapy, and 36 of 45 (80%) eligible early-stage breast cancer patients accepted neoadjuvant hormonal therapy during the period that elective cancer surgery was on hold. Patients received radiation therapy less frequently during the pandemic. The proportion of patients diagnosed with invasive ductal cancers was higher in the 2020 cohort and the proportion of patients diagnosed with ductal carcinoma in situ (DCIS) and for invasive lobular cancers (ILC) was lower. Conclusions: Patients at an academic New York City medical center presented with more palpable and invasive breast cancers during the COVID-19 pandemic compared to the preceding year, and fewer patients with DCIS and ILC, cancers typically detected following screening mammography. While stage migration with an increase in diagnosis of late stage cancers has been described, in our population the stage shift occurred in early stage breast cancer, with decreases in DCIS and increases in Stages I-II, with the higher stages III-IV essentially unchanged. This reflects the effect of delay in our previously highly-screened population, with an average screening delay of 3 + months, and many patients missing their yearly screening altogether. While many medical interactions during COVID-19 were via telemedicine, radiation therapy requires daily office visits, and fear of exposure contributed to the lower rate of radiation. Given the increase in invasiveness and stage of breast cancers diagnosed during the COVID-19 pandemic, this study emphasizes the importance of screening for diagnosis and treatment of breast cancer, even in the face of a concurrent health crisis. Variable2019 Population N=3492020 Population N=246P-ValueMethod of DetectionSelf-Exam19.80%26.0%0.0688Mammography67.0%60.0%Palpability31.50%39.20%0.0533Neoadjuvant Therapy8.30%10.20%0.4384Radiation Therapy65.0%54%<0.0001Age at presentation60.0460.680.6171Type of surgeryBreast Conserving Surgery69%66%<0.8508Mastectomy31%34%HistologyIDC60.70%66.7%0.5822DCIS20.9%16.7%ILC10.6%8.10% Citation Format: Amber Azniv Guth, Brian Diskin, Freya Schnabel, Nakisa Pourkey, Deborah Axelrod, Richard Shapiro. Changes in breast cancer presentation during Covid-19: Experience in an Urban Academic Center [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-03-01.

Changes in Breast Cancer Presentation during COVID-19: Experience in an Urban Academic Center

“…The aim of this study was to determine how the COVID-19 pandemic and the ensuing lockdowns, reallocation of healthcare resources, and delays in breast cancer screening and treatment altered the presentation and oncologic treatment of breast cancer at our urban academic medical center in NYC, the epicenter of the early phase of the pandemic in the US [12].…”